Ocuphire Pharma ( (OCUP) ) just unveiled an update.

Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for inherited retinal diseases (IRDs). This strategic move will see the company renamed Opus Genetics, Inc. and trading under the ticker ‘IRD.’ With promising early data, the merger brings together a strong leadership team to advance groundbreaking therapies, while extending the cash runway into 2026. Investors can expect significant clinical milestones in 2025, including trials for LCA5, BEST1, and other ophthalmic conditions.

Learn more about OCUP stock on TipRanks’ Stock Analysis page.